Dr. Lui Franciosi reports

DR. MICHAEL K. PUGSLEY JOINS VERITAS PHARMA'S ADVISORY BOARD

Dr. Michael K. Pugsley, PhD, FBPhS, DSP, a consultant in safety pharmacology, has joined Veritas Pharma Inc.'s advisory board. Dr. Pugsley is a safety pharmacologist and toxicologist specialized in a variety of therapeutic areas in drug development, in particular, central nervous system, anti-inflammatory, oncology, myocardial infarction and congestive heart failure.

Veritas chief executive officer Dr. Lui Franciosi stated: "Dr. Pugsley brings exceptional knowledge and experience both in academia and industry in the area of pharmacology. He will advise us on how to best position the company's therapeutic cannabis strains in medical practice as well as assist scientists at our research arm, Cannevert Therapeutics Ltd., with their current research projects."

Dr. Pugsley was the former director of toxicology at Purdue Pharma LP, a privately held pharmaceutical company with an innovative product portfolio of medications for pain management, including its most notable product OxyContin. He led the PKDM/toxicology department in planning and execution of all non-clinical toxicology and safety pharmacology studies in support of drug development and marketed products. Prior to that, he had developed broad experience from large and specialty pharmaceutical companies, including experience preparing IND and NDA submissions and conducting technical assessments of pharmacology, toxicology and safety pharmacology data in support of licensing candidates. He was previously at Johnson and Johnson as the scientific director and research fellow for toxicology/pathology and global safety pharmacology in drug safety sciences. He also worked at Forest Pharmaceuticals as a senior principal scientist. Earlier in his career, he was a senior scientist with XOMA (U.S.) LLC. He holds a PhD in cardiac electrophysiology, an MSc in eicosanoid pharmacology and a BSc in human pharmacology from the University of British Columbia, Vancouver, Canada.

Veritas Pharma aims to utilize Dr. Pugsley's knowledge and expertise of safety pharmacology, especially with respect to analgesics, along with the help of its medical director, Dr. Scott Alexander, in providing physicians and patients with the best clinical advice on the use of its scientifically tested and clinically proven cannabis therapies. His advice and guidance will help the company's efforts in bringing new therapeutic strains to market in the coming months and years.

About Veritas Pharma Inc.

Veritas Pharma is an emerging pharmaceutical and intellectual property development company, which, through its 100-per-cent-owned subsidiary Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis.